Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

RNAi Returns To Spotlight As Novo Nordisk Swoops For Dicerna

Paying $3.3bn

Nov 18 2021

• By Kevin Grogan

Novo Nordisk — • Source: Archive

Related Content

Roche Secures Dicerna RNAi Deal For Hepatitis B

Nov 01 2019

Alnylam CEO Maraganore To Step Aside At End Of 2021

Oct 28 2021

EU First To Approve Novartis’s Cholesterol Drug Leqvio

Dec 11 2020

Related Companies

Novo Nordisk A/S

Dicerna Pharmaceuticals, Inc.

Eli Lilly and Company

Boehringer Ingelheim GmbH

AstraZeneca PLC

Alnylam Pharmaceuticals Inc.

Roche Holding AG

Arrowhead Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

Wave Life Sciences Ltd.

Novartis AG

Additional Topics

M & A Business Strategies Commercial Deals Liver & Hepatic Metabolic Disorders BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.